AG
ALNY icon

AIA Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

AIA Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33M Hold
7,742
– – 0.03% 202
2026
Q1 		$2.56M Sell
7,742
-12,435
-62% -$4.23M 0.04% 206
2025
Q4 		$8.02M Sell
20,177
-13,136
-39% -$5.81M 0.12% 115
2025
Q3 		$15.2M Buy
33,313
+3,081
+10% +$1.25M 0.27% 59
2025
Q2 		$9.86M Buy
30,232
+3,741
+14% +$1.04M 0.21% 60
2025
Q1 		$7.15M Buy
26,491
+3,643
+16% +$936K 0.18% 68
2024
Q4 		$5.38M Sell
22,848
-5,369
-19% -$1.41M 0.13% 77
2024
Q3 		$7.76M Buy
28,217
+8,789
+45% +$2.29M 0.2% 58
2024
Q2 		$4.72M Buy
19,428
+4,784
+33% +$755K 0.14% 81
2024
Q1 		$2.19M Hold
14,644
– – 0.07% 129
2023
Q4 		$2.8M Hold
14,644
– – 0.12% 87
2023
Q3 		$2.59M Buy
14,644
+2,050
+16% +$391K 0.13% 85
2023
Q2 		$2.39M Buy
12,594
+6,910
+122% +$1.37M 0.12% 86
2023
Q1 		$1.14M Buy
5,684
+685
+14% +$144K 0.06% 139
2022
Q4 		$1.19M Buy
4,999
+1,075
+27% +$229K 0.07% 117
2022
Q3 		$785K Buy
3,924
+1,039
+36% +$198K 0.05% 151
2022
Q2 		$421K Buy
+2,885
New +$409K 0.02% 257

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AIA Group's ALNY Position: Q2 2026 in Review

AIA Group held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 7,742 shares worth $2.33M. The position accounts for 0.03% of the portfolio, ranked #202.

AIA Group first reported a position in ALNY in Q2 2022 and has held it in 17 quarters since. The position peaked at $15.2M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • AIA Group held 7,742 shares of Alnylam Pharmaceuticals worth $2.33M as of Q2 2026.
  • AIA Group left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.03% of AIA Group's portfolio in Q2 2026, its #202 holding.
  • AIA Group first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • AIA Group's Alnylam Pharmaceuticals position peaked at $15.2M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on AIA Group's 13F filing for Q2 2026, filed 31 Jul 2026.